QP not present in Company: Prohibition of Supply
Recommendation

2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
A new Non-Compliance Report (NCR, Report No: 2017090955) was published on the EudraGMDP site. On 21 September 2017, the Danish Medicines Agency performed an inspection at EuroPharma.DK ApS in Denmark. EuroPharma.DK ApS performs parallel import, repacking and distribution of pharmaceutical products.
During that inspection, it was considered that the secondary packing operations at the site do not comply with Good Manufacturing Practice. This was also based on the following observations:
- QP not present in company for supervision and competent interaction with staff and management
- QA department understaffed
- Inadequate follow-up and implementation of CAPAs
- Insufficient handling of deviations and complaints
- Inadequate GDP implementation
As a consequence, the respective manufacturing authorisation was suspended and medicinal products must not be re-packed by EuroPharma DK or any of their contract manufacturers and must not be released and distributed. What's interesting is the fact that the GMP certificate which was withdrawn was just issued after an inspection on 8 March 2017.
Source: EudraGMDP Database (Report # 2017090955)
Related GMP News
15.07.2026Root Cause Analysis and CAPA: Two more Warning Letters issued to Companies in Europe
01.07.2026EMA publishes updated Q&A on EU-US MRA - Veterinary Medicinal Products now fully covered
24.06.2026Reduced Testing a Matter of GMP or Specification?
17.06.2026FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)
10.06.2026European QP Association Developments January through April 2026
15.04.2026ICH Q9 Training Package updated


